X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9) 9
humans (7) 7
animals (5) 5
cell biology (5) 5
mice (5) 5
stem cells (5) 5
female (4) 4
hematology (4) 4
hemic and lymphatic diseases (4) 4
male (4) 4
clinical medicine (3) 3
gene expression (3) 3
hematopoietic stem cells (3) 3
klinisk medicin (3) 3
leukemia (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
middle aged (3) 3
myelodysplastic syndromes (3) 3
oncology (3) 3
aged (2) 2
aged, 80 and over (2) 2
benzoates - administration & dosage (2) 2
beta-thalassemia (2) 2
bone marrow (2) 2
cancer and oncology (2) 2
cancer och onkologi (2) 2
cells, cultured (2) 2
deferiprone (2) 2
embryonic structures (2) 2
flt3 ligand (2) 2
fms-like tyrosine kinase 3 - genetics (2) 2
hematopoietic stem cells - drug effects (2) 2
hematopoietic stem cells - metabolism (2) 2
hemic and immune systems (2) 2
heterogeneity (2) 2
impact (2) 2
iron overload - drug therapy (2) 2
iron overload - etiology (2) 2
long-term therapy (2) 2
major patients (2) 2
medicine, general & internal (2) 2
mice, inbred c57bl (2) 2
mice, inbred nod (2) 2
mice, transgenic (2) 2
mutation (2) 2
mutations (2) 2
myelodysplastic syndromes - pathology (2) 2
myocardial iron (2) 2
progenitors (2) 2
randomized controlled trials as topic (2) 2
randomized controlled-trial (2) 2
right-ventricular function (2) 2
stem-cells (2) 2
thalassemia - therapy (2) 2
thalassemia [therapy] (2) 2
transferrin-bound iron (2) 2
treatment outcome (2) 2
304 (1) 1
308 (1) 1
315 (1) 1
abridged index medicus (1) 1
acute myeloid leukemia (1) 1
acute myeloid-leukemia (1) 1
administration, oral (1) 1
adult (1) 1
amino acid substitution - physiology (1) 1
analysis (1) 1
anti-inflammatory agents, non-steroidal - pharmacology (1) 1
antibodies (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibody (1) 1
antigens, cd - biosynthesis (1) 1
antigens, cd - immunology (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
article (1) 1
artificial chromosomes (1) 1
azacitidine (1) 1
azacitidine - administration & dosage (1) 1
azacitidine - adverse effects (1) 1
b-cell (1) 1
benzoates - adverse effects (1) 1
bias (1) 1
biologi (1) 1
biological sciences (1) 1
biology (1) 1
blood platelets (1) 1
blood platelets - cytology (1) 1
blood platelets - drug effects (1) 1
blood platelets - pathology (1) 1
blood transfusion [adverse effects] (1) 1
body regions (1) 1
bone (1) 1
bone marrow cells - drug effects (1) 1
bone marrow cells - metabolism (1) 1
bone marrow transplantation (1) 1
bone-marrow niche (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 07/2017, Volume 214, Issue 7, pp. 2005 - 2021
Although previous studies suggested that the expression of FMS-like tyrosine kinase 3 (Flt3) initiates downstream of mouse hematopoietic stem cells (HSCs),... 
PROGENITOR CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | T-SNE | GENE | MULTIPOTENT PROGENITORS | BONE-MARROW NICHE | NECROSIS-FACTOR-ALPHA | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | FLT3 LIGAND | DIFFERENTIAL EXPRESSION ANALYSIS | MYELODYSPLASTIC SYNDROMES | Hematopoietic Stem Cells - drug effects | Tumor Necrosis Factor-alpha - metabolism | Cell Proliferation - genetics | Mice, Inbred C57BL | Tumor Necrosis Factor-alpha - genetics | Cells, Cultured | Gene Expression Profiling - methods | Mice, Transgenic | Hematopoietic Stem Cells - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | fms-Like Tyrosine Kinase 3 - genetics | Animals | Single-Cell Analysis - methods | Etanercept - pharmacology | Mesenchymal Stem Cells - drug effects | Bone Marrow Transplantation | Bone Marrow Cells - drug effects | Mutation | Mesenchymal Stem Cells - metabolism | Stem Cell Niche - genetics | Tandem Repeat Sequences - genetics | Bone Marrow Cells - metabolism | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Tyrosine | Mesenchyme | Myeloid leukemia | Leukemia | Stem cell transplantation | Transplantation | Myeloproliferation | Kinases | Gene expression | Hematopoietic stem cells | Tumor necrosis factor | Stromal cells | Interrogation | Stem cells | Bone marrow | Tumor necrosis factor-TNF | Reservoirs | Mice | Flt3 protein | Bone | Acute myeloid leukemia | Protein-tyrosine kinase | 315 | 304 | 308
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2014, Volume 25, Issue 6, pp. 794 - 808
Journal Article
Journal Article
Journal Article
Cell Reports, ISSN 2211-1247, 06/2013, Volume 3, Issue 6, pp. 1766 - 1776
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3037 - 3037
Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterised by the frequent presence of driver mutations in genes causing... 
Journal Article
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 20, pp. 4156 - 4165
Journal Article
European Journal of Haematology, ISSN 0902-4441, 11/2014, Volume 93, Issue 5, pp. 439 - 445
Objectives Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS). Azacitidine, first‐line treatment for... 
thrombocytopenia | eltrombopag | Myelodysplastic syndrome | azacitidine | thrombopoietin‐receptor | Thrombocytopenia | Thrombopoietin-receptor | Eltrombopag | Azacitidine | LEUKEMIA GROUP-B | SURVIVAL | STEM-CELLS | IMPACT | thrombopoietin-receptor | PROLIFERATION | HEMATOLOGY | CANCER | Blood Platelets - pathology | Benzoates - adverse effects | Azacitidine - adverse effects | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Thrombocytopenia - complications | Thrombocytopenia - drug therapy | Antineoplastic Agents - adverse effects | Ischemic Attack, Transient - etiology | Aged, 80 and over | Female | Blood Platelets - drug effects | Drug Therapy, Combination | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Ischemic Attack, Transient - pathology | Pyrazoles - adverse effects | Hematopoietic Stem Cells - drug effects | Myelodysplastic Syndromes - metabolism | Treatment Outcome | Thrombocytopenia - pathology | Myelodysplastic Syndromes - complications | Receptors, Thrombopoietin - metabolism | Remission Induction | Thrombocytopenia - metabolism | Venous Thrombosis - etiology | Benzoates - administration & dosage | Drug Synergism | Receptors, Thrombopoietin - agonists | Pilot Projects | Pyrazoles - administration & dosage | Platelet Count | Aged | Venous Thrombosis - pathology | Cell Cycle - drug effects | Myelodysplastic Syndromes - pathology | Hydrazines - adverse effects | Antimitotic agents | Medical research | Complications and side effects | Care and treatment | Safety and security measures | Leukemia | Clinical trials | Medicine, Experimental | Antineoplastic agents | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
Journal Article